Doxazosin
Cat.No:ID1160 Solarbio
CAS:77883-43-3
Molecular Formula:C24H29N5O8S
Molecular Weight:547.58
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Endocrinology & Hormones >
DoxazosinCAS:77883-43-3
Molecular Formula:C24H29N5O8S
Molecular Weight:547.58
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 77883-43-3 |
Name | Doxazosin |
Molecular Formula | C24H29N5O8S |
Molecular Weight | 547.58 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 1308068-626-2 |
MDL | MFCD00216023 |
SMILES | O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OC5=CC=CC=C5OC4.CS(=O)(O)=O |
InChIKey | VJECBOKJABCYMF-UHFFFAOYSA-N |
InChI | InChI=1S/C23H25N5O5.CH4O3S/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20;1-5(2,3)4/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26);1H3,(H,2,3,4) |
PubChem CID | 62978 |
Target Point | Adrenergic Receptor |
Passage | Endocrinology & Hormones;GPCR & G Protein;Neuronal Signaling |
Background | It selectively antagonizes postsynaptic α1 adrenergic receptors. |
Biological Activity | Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic聽伪1-adrenergic receptors. |
IC50 | α adrenergic receptor |
Data Literature Source | [1]. Sun,J.A.,et al.,Stereoselective binding of doxazosin enantiomers to plasma proteins from rats,dogs and humans in vitro. Acta Pharmacol Sin,2013. 34(12): p. 1568-74. [2]. D'Eletto,R.D. and N.B. Javitt,Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol,1989. 13 Suppl 2: p. S1-4; discussion S4. [3]. Miura,Y. and K. Yoshinaga,Doxazosin: a newly developed,selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J,1988. 116(6 Pt 2): p. 1785-9. |
Unit | Bottle |
Specification | 100mg 500mg 1g |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.